8:32 am Kindred Biosciences announces positive results from pivotal study of KIND-010 for the management of weight loss in cats (KIN) :
Co announced positive topline results from its pivotal field study of KIND-010, mirtazapine transdermal gel, for the management of weight loss in cats. This study, KB105, was a multicenter, randomized, double-blind, placebo-controlled pivotal field study that enrolled 231 cats to assess the effectiveness of KIND-010 in stimulating weight gain in cats. The primary endpoint was percentage change in body weight from Day 1 to Week 2. At Week 2, the mean percent increase in body weight from Day 1 was 4.07% in the KIND-010 group (n=90), versus 0.29% in the placebo group (n=97) (p<0.0001). Based on a preliminary review of the safety data, the drug appears to be well tolerated. The Company plans to file the Effectiveness Technical Section with the data from the KB105 pivotal field study with the Food and Drug Administration in the third quarter of 2016.
I suppose we'll see face lifts for Fido in the nonce.
No comments:
Post a Comment